Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...

The firm said the clinical trial pause is temporary as an independent data monitoring committee finalizes its analysis for submission to regulators.

Key Takeaways Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European ...

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...

Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...

A pair of Scottsdale brothers have launched an online site to help address what they consider an oft-forgotten part of the ...

Some locals will be embarking on an ambitious journey down the Rogue River later this month for a good cause. A group of ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

Healthcare Analysts, along with Dr. Yaacov Anziske of SUNY Downstate, discuss Sarepta’s (SRPT) ELEVIDYS and the future of Duchenne Muscular ...

On April 25, Joe Jackson and a dedicated crew of men including Jeremy Leever and Shaun Olson will embark on an extraordinary ...

Doing more to incorporate caregiver burden into value assessments and cost-effectiveness research of Duchene muscular dystrophy treatments was the focus of a recent International Society for ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...